Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy

Elizabeth A. Chrischilles, Donald G. Klepser, John M. Brooks, Margaret D. Voelker, Shari S. Chen-Hardee, Shane D. Scott, Brian K. Link, David J. Delgado

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Study Objective. To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs. Design. Retrospective cohort study. Data Source. Linked Surveillance, Epidemiology, and End Results Program-Healthcare Cost and Utilization Project databases for Iowa from 1993-1998. Patients. Patients with newly diagnosed non-Hodgkin's lymphoma who received all inpatient care at Iowa hospitals during their first course of chemotherapy. Measurements and Main Results. Neutropenia-related hospitalization costs were estimated from discharge abstracts found within the earliest of the following: 6 months after the diagnosis month, the date of bone marrow transplantation, or date of death. We performed univariate tests of differences in neutropenia-related hospitalization costs in all patients in the sample, as well as tests for neutropenia-related hospitalization costs, length-of-stay, and cost/inpatient day for patients with at least one hospitalization for neutropenia. We modeled total inpatient charges over the period for patients with at least one neutropenia-related hospitalization (multiple regression). A total of 1636 patients with non-Hodgkin's lymphoma had chemotherapy in Iowa and met inclusion criteria; of these, 316 had at least one hospitalization for neutropenia. The 316 patients had 418 stays. Patients with advanced stage (vs limited stage), previous anemia (vs no anemia), positive Charlson comorbidity score (vs score of 0), and diffuse large cell histology (vs follicular) had higher mean neutropenia-related hospitalization cost/patient with non-Hodgkin's lymphoma (p<0.05). Among those with neutropenia-related hospitalizations, a longer length of stay was associated with nonfollicular histologies, previous anemia, and positive Charlson score (p<0.05). Conclusion. When estimating expected payments for neutropenia-related hospitalization in patients with non-Hodgkin's lymphoma, payers need to be aware of the distribution of clinical characteristics in these patients.

Original languageEnglish (US)
Pages (from-to)668-675
Number of pages8
JournalPharmacotherapy
Volume25
Issue number5 I
DOIs
StatePublished - May 1 2005

Fingerprint

Neutropenia
Non-Hodgkin's Lymphoma
Inpatients
Costs and Cost Analysis
Drug Therapy
Hospitalization
Anemia
Length of Stay
Histology
SEER Program
Hospital Distribution Systems
Information Storage and Retrieval
Bone Marrow Transplantation
Health Care Costs
Comorbidity
Cohort Studies
Retrospective Studies
Databases

Keywords

  • And End Results Program
  • Epidemiology
  • HCUP
  • Healthcare Cost and Utilization Project
  • Hospitalization costs
  • Linked databases
  • Neutropenia
  • Non-Hodgkin's lymphoma
  • SEER Program
  • Surveillance

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. / Chrischilles, Elizabeth A.; Klepser, Donald G.; Brooks, John M.; Voelker, Margaret D.; Chen-Hardee, Shari S.; Scott, Shane D.; Link, Brian K.; Delgado, David J.

In: Pharmacotherapy, Vol. 25, No. 5 I, 01.05.2005, p. 668-675.

Research output: Contribution to journalArticle

Chrischilles, Elizabeth A. ; Klepser, Donald G. ; Brooks, John M. ; Voelker, Margaret D. ; Chen-Hardee, Shari S. ; Scott, Shane D. ; Link, Brian K. ; Delgado, David J. / Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. In: Pharmacotherapy. 2005 ; Vol. 25, No. 5 I. pp. 668-675.
@article{f1269509bbd149499fcfe0e6eedd970d,
title = "Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy",
abstract = "Study Objective. To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs. Design. Retrospective cohort study. Data Source. Linked Surveillance, Epidemiology, and End Results Program-Healthcare Cost and Utilization Project databases for Iowa from 1993-1998. Patients. Patients with newly diagnosed non-Hodgkin's lymphoma who received all inpatient care at Iowa hospitals during their first course of chemotherapy. Measurements and Main Results. Neutropenia-related hospitalization costs were estimated from discharge abstracts found within the earliest of the following: 6 months after the diagnosis month, the date of bone marrow transplantation, or date of death. We performed univariate tests of differences in neutropenia-related hospitalization costs in all patients in the sample, as well as tests for neutropenia-related hospitalization costs, length-of-stay, and cost/inpatient day for patients with at least one hospitalization for neutropenia. We modeled total inpatient charges over the period for patients with at least one neutropenia-related hospitalization (multiple regression). A total of 1636 patients with non-Hodgkin's lymphoma had chemotherapy in Iowa and met inclusion criteria; of these, 316 had at least one hospitalization for neutropenia. The 316 patients had 418 stays. Patients with advanced stage (vs limited stage), previous anemia (vs no anemia), positive Charlson comorbidity score (vs score of 0), and diffuse large cell histology (vs follicular) had higher mean neutropenia-related hospitalization cost/patient with non-Hodgkin's lymphoma (p<0.05). Among those with neutropenia-related hospitalizations, a longer length of stay was associated with nonfollicular histologies, previous anemia, and positive Charlson score (p<0.05). Conclusion. When estimating expected payments for neutropenia-related hospitalization in patients with non-Hodgkin's lymphoma, payers need to be aware of the distribution of clinical characteristics in these patients.",
keywords = "And End Results Program, Epidemiology, HCUP, Healthcare Cost and Utilization Project, Hospitalization costs, Linked databases, Neutropenia, Non-Hodgkin's lymphoma, SEER Program, Surveillance",
author = "Chrischilles, {Elizabeth A.} and Klepser, {Donald G.} and Brooks, {John M.} and Voelker, {Margaret D.} and Chen-Hardee, {Shari S.} and Scott, {Shane D.} and Link, {Brian K.} and Delgado, {David J.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1592/phco.25.5.668.63586",
language = "English (US)",
volume = "25",
pages = "668--675",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5 I",

}

TY - JOUR

T1 - Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy

AU - Chrischilles, Elizabeth A.

AU - Klepser, Donald G.

AU - Brooks, John M.

AU - Voelker, Margaret D.

AU - Chen-Hardee, Shari S.

AU - Scott, Shane D.

AU - Link, Brian K.

AU - Delgado, David J.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Study Objective. To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs. Design. Retrospective cohort study. Data Source. Linked Surveillance, Epidemiology, and End Results Program-Healthcare Cost and Utilization Project databases for Iowa from 1993-1998. Patients. Patients with newly diagnosed non-Hodgkin's lymphoma who received all inpatient care at Iowa hospitals during their first course of chemotherapy. Measurements and Main Results. Neutropenia-related hospitalization costs were estimated from discharge abstracts found within the earliest of the following: 6 months after the diagnosis month, the date of bone marrow transplantation, or date of death. We performed univariate tests of differences in neutropenia-related hospitalization costs in all patients in the sample, as well as tests for neutropenia-related hospitalization costs, length-of-stay, and cost/inpatient day for patients with at least one hospitalization for neutropenia. We modeled total inpatient charges over the period for patients with at least one neutropenia-related hospitalization (multiple regression). A total of 1636 patients with non-Hodgkin's lymphoma had chemotherapy in Iowa and met inclusion criteria; of these, 316 had at least one hospitalization for neutropenia. The 316 patients had 418 stays. Patients with advanced stage (vs limited stage), previous anemia (vs no anemia), positive Charlson comorbidity score (vs score of 0), and diffuse large cell histology (vs follicular) had higher mean neutropenia-related hospitalization cost/patient with non-Hodgkin's lymphoma (p<0.05). Among those with neutropenia-related hospitalizations, a longer length of stay was associated with nonfollicular histologies, previous anemia, and positive Charlson score (p<0.05). Conclusion. When estimating expected payments for neutropenia-related hospitalization in patients with non-Hodgkin's lymphoma, payers need to be aware of the distribution of clinical characteristics in these patients.

AB - Study Objective. To estimate the costs of hospitalization for neutropenia among chemotherapy-treated patients with newly diagnosed non-Hodgkin's lymphoma and to assess baseline patient factors associated with these costs. Design. Retrospective cohort study. Data Source. Linked Surveillance, Epidemiology, and End Results Program-Healthcare Cost and Utilization Project databases for Iowa from 1993-1998. Patients. Patients with newly diagnosed non-Hodgkin's lymphoma who received all inpatient care at Iowa hospitals during their first course of chemotherapy. Measurements and Main Results. Neutropenia-related hospitalization costs were estimated from discharge abstracts found within the earliest of the following: 6 months after the diagnosis month, the date of bone marrow transplantation, or date of death. We performed univariate tests of differences in neutropenia-related hospitalization costs in all patients in the sample, as well as tests for neutropenia-related hospitalization costs, length-of-stay, and cost/inpatient day for patients with at least one hospitalization for neutropenia. We modeled total inpatient charges over the period for patients with at least one neutropenia-related hospitalization (multiple regression). A total of 1636 patients with non-Hodgkin's lymphoma had chemotherapy in Iowa and met inclusion criteria; of these, 316 had at least one hospitalization for neutropenia. The 316 patients had 418 stays. Patients with advanced stage (vs limited stage), previous anemia (vs no anemia), positive Charlson comorbidity score (vs score of 0), and diffuse large cell histology (vs follicular) had higher mean neutropenia-related hospitalization cost/patient with non-Hodgkin's lymphoma (p<0.05). Among those with neutropenia-related hospitalizations, a longer length of stay was associated with nonfollicular histologies, previous anemia, and positive Charlson score (p<0.05). Conclusion. When estimating expected payments for neutropenia-related hospitalization in patients with non-Hodgkin's lymphoma, payers need to be aware of the distribution of clinical characteristics in these patients.

KW - And End Results Program

KW - Epidemiology

KW - HCUP

KW - Healthcare Cost and Utilization Project

KW - Hospitalization costs

KW - Linked databases

KW - Neutropenia

KW - Non-Hodgkin's lymphoma

KW - SEER Program

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=18044393205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044393205&partnerID=8YFLogxK

U2 - 10.1592/phco.25.5.668.63586

DO - 10.1592/phco.25.5.668.63586

M3 - Article

C2 - 15899728

AN - SCOPUS:18044393205

VL - 25

SP - 668

EP - 675

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5 I

ER -